STING-Mediated Lung Inflammation and Beyond
- PMID: 33532887
- DOI: 10.1007/s10875-021-00974-z
STING-Mediated Lung Inflammation and Beyond
Abstract
Mendelian autoinflammatory diseases characterized by constitutive activation of the type I interferon pathway, the so-called type I interferonopathies, constitute a rapidly expanding group of inborn errors of immunity. Among the type I interferonopathies, STING-associated vasculopathy with onset in infancy (SAVI) and COPA syndrome were described in the last 6 years, both manifesting a major inflammatory lung component associated with significant morbidity and increased mortality. There is striking clinical and histopathological overlap between SAVI and COPA syndrome, although distinct features are also present. Of note, there is a remarkably high frequency of clinical non-penetrance among individuals harboring pathogenic COPA mutations. SAVI is caused by, principally heterozygous, gain-of-function mutations in STING1 (previously referred to as TMEM173) encoding STING, a key adaptor of the interferon signaling pathway induced by DNA. COPA syndrome results from heterozygous dominant-negative mutations in the coatomer protein subunit alpha, forming part of a complex involved in intracellular cargo protein transport between the Golgi and the endoplasmic reticulum (ER). Of importance, a role for COPA in regulating the trafficking of STING, an ER-resident protein which translocates to the Golgi during the process of its activation, was recently defined, thereby possibly explaining some aspects of the phenotypic overlap between SAVI and COPA syndrome. Here, we review the expanding phenotype of these diseases, highlighting common as well as specific features, and recent advances in our understanding of STING biology that have informed therapeutic decision-making in both conditions. Beyond these rare Mendelian disorders, DNA sensing through STING is likely relevant to the pathology of several diseases associated with lung inflammation, including systemic lupus erythematosus, dermatomyositis, environmental toxin exposure, and viral infection.
Keywords: COPA; SAVI; STING; alveolar hemorrhage; interstitial lung disease; lung inflammation.
Similar articles
-
Lung Inflammation in STING-Associated Vasculopathy with Onset in Infancy (SAVI).Cells. 2022 Jan 18;11(3):318. doi: 10.3390/cells11030318. Cells. 2022. PMID: 35159128 Free PMC article. Review.
-
Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling.J Exp Med. 2020 Nov 2;217(11):e20200600. doi: 10.1084/jem.20200600. J Exp Med. 2020. PMID: 32725128 Free PMC article.
-
A defect in COPI-mediated transport of STING causes immune dysregulation in COPA syndrome.J Exp Med. 2020 Nov 2;217(11):e20201045. doi: 10.1084/jem.20201045. J Exp Med. 2020. PMID: 32725126 Free PMC article.
-
STING Operation at the ER/Golgi Interface.Front Immunol. 2021 May 3;12:646304. doi: 10.3389/fimmu.2021.646304. eCollection 2021. Front Immunol. 2021. PMID: 34012437 Free PMC article. Review.
-
Cell biological insights into human STING variants.Cell Struct Funct. 2025 Jun 7;50(1):135-144. doi: 10.1247/csf.25020. Epub 2025 May 14. Cell Struct Funct. 2025. PMID: 40368781 Review.
Cited by
-
Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases.Nat Rev Rheumatol. 2021 Jul;17(7):405-425. doi: 10.1038/s41584-021-00614-1. Epub 2021 May 25. Nat Rev Rheumatol. 2021. PMID: 34035534 Review.
-
STING trafficking as a new dimension of immune signaling.J Exp Med. 2023 Mar 6;220(3):e20220990. doi: 10.1084/jem.20220990. Epub 2023 Jan 27. J Exp Med. 2023. PMID: 36705629 Free PMC article.
-
The type I interferonopathies: 10 years on.Nat Rev Immunol. 2022 Aug;22(8):471-483. doi: 10.1038/s41577-021-00633-9. Epub 2021 Oct 20. Nat Rev Immunol. 2022. PMID: 34671122 Free PMC article. Review.
-
Monogenic autoinflammatory disease-associated cardiac damage.Inflamm Res. 2023 Aug;72(8):1689-1693. doi: 10.1007/s00011-023-01771-7. Epub 2023 Aug 10. Inflamm Res. 2023. PMID: 37563333 Review.
-
Cytoplasmic DNAs: Sources, sensing, and roles in the development of lung inflammatory diseases and cancer.Front Immunol. 2023 Apr 12;14:1117760. doi: 10.3389/fimmu.2023.1117760. eCollection 2023. Front Immunol. 2023. PMID: 37122745 Free PMC article. Review.
References
-
- Uggenti C, Lepelley A, Crow YJ. Self-awareness: nucleic acid-driven inflammation and the type I interferonopathies. Annu Rev Immunol. 2019;37:247–67. - PubMed
-
- Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011;1238:91–8. - PubMed
-
- Melki I, Frémond M-L. Type I interferonopathies: from a novel concept to targeted therapeutics. Curr Rheumatol Rep. 2020;22:32. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials